Melatonin receptor agonists: New options for insomnia and depression treatment

CNS Neuroscience and Therapeutics

Volumn 17, Issue 6, 2011, Pages 733-741

  Spadoni, Gilberto ^a   Bedini, Annalida ^a   Rivara, Silvia ^b   Mor, Marco ^b  

^a UNIVERSITY OF URBINO   (Italy)

^b UNIVERSITY OF PARMA   (Italy)

Author keywords

Depression; Melatonin; Melatonin receptor agonists; MT 1 receptor; MT 2 receptor; Sleep disorder

Indexed keywords

AGOMELATINE; HORMONE RECEPTOR STIMULATING AGENT; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN RECEPTOR; MELATONIN RECEPTOR AGONIST; RAMELTEON; TASIMELTEON; TIK 301; UNCLASSIFIED DRUG;

CIRCADIAN RHYTHM; CLINICAL TRIAL (TOPIC); DEPRESSION; DRUG RECEPTOR BINDING; DRUG STRUCTURE; HUMAN; INSOMNIA; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SLEEP DISORDER; SLEEP WAKING CYCLE; SUPRACHIASMATIC NUCLEUS;

ANIMALS; DEPRESSIVE DISORDER; DEPRESSIVE DISORDER, MAJOR; DRUG DESIGN; HUMANS; MELATONIN; RECEPTORS, MELATONIN; SLEEP INITIATION AND MAINTENANCE DISORDERS; SUBSTRATE SPECIFICITY;

EID: 82355191864     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2010.00197.x     Document Type: Review

References (121)

1. Lerner AB, Case JD. Structure of melatonin. J Am Chem Soc 1959;81:6084-6085.
2. Inouye ST, Kawamura H. Persistence of circadian rhythmicity in a mammalian hypothalamic "island" containing the suprachiasmatic nucleus. Proc Natl Acad Sci USA 1979;76:5962-5966.
3. Kvetnoy IM. Extrapineal melatonin: Location and role within diffuse neuroendocrine system. Histochem J 1999;31:1-12.
4. 7 melatonin. Biopharm Drug Dispos 2000;21:15-22.
5. Reiter RJ. Comparative physiology: Pineal gland. Annu Rev Physiol 1973;35:305-328.
6. Abecia JA, Forcada F, Casao A, Palacin I. Effect of exogenous melatonin on the ovary, the embryo and the establishment of pregnancy in sheep. Animal 2008;2:399-404.
7. Arendt J. Melatonin: Characteristics, concerns, and prospects. J Biol Rhythms 2005;20:291-303.
8. Srinivasan V, Smits M, Spence W, et al. Melatonin in mood disorders. World J Biol Psychiatry 2006;7:138-151.
9. Maestroni GJ. The immunotherapeutic potential of melatonin. Expert Opin Invest Drugs 2001;10:467-476.
10. Simko F, Pechanova O. Potential roles of melatonin and chronotherapy among the new trends in hypertension treatment. J Pineal Res 2009;47:127-133.
11. Ambriz-Tututi M, Rocha-González HI, Cruz SL, Granados-Soto V. Melatonin: A hormone that modulates pain. Life Sci 2009;84:489-498.
12. 1-acetyl-5-methoxykynuramine (AMK), in macrophages. J Neuroimmunol 2005;165:139-149.
13. Hardeland R. Antioxidative protection by melatonin: Multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine 2005;27:119-130.
14. Hardeland R. Neuroprotection by radical avoidance: Search for suitable agents. Molecules 2009;14:5054-5102.
15. Mills E, Wu P, Seely D, Guyatt G. Melatonin in the treatment of cancer: A systematic review of randomized controlled trials and meta-analysis. J Pineal Res 2005;39:360-366.
16. Bouatia-Naji N, Bonnefond A, Cavalcanti-Proença C, et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet 2009;41:89-94.
17. Mulder H, Nagorny CL, Lyssenko V, Groop L. Melatonin receptors in pancreatic islets: Good morning to a novel type 2 diabetes gene. Diabetologia 2009;52:1240-1249.
18. Niles LP, Wong Y-W, Mishra RK, Brown GM. Melatonin receptors in brain. Eur J Pharmacol 1979;55:219-220.
19. Vakkuri O, Lämsä E, Rahkamaa E, Ruotsalainen H, Leppäluoto J. Iodinated melatonin: Preparation and characterization of the molecular structure by mass and 1H NMR spectroscopy. Anal Biochem 1984;142:284-289.
20. Morgan PJ, Barrett P, Howell HE, Helliwell R. Melatonin receptors: Localization, molecular pharmacology and physiological significance. Neurochem Int 1994;24:101-146.
21. 2 melatonin receptors in mammals. Endocrine 2005;27:101-110.
22. Ebisawa T, Karne S, Lerner MR, Reppert SM. Expression cloning of a high-affinity melatonin receptor from Xenopus dermal melanophores. Proc Natl Acad Sci USA 1994;91:6133-6137.
23. Reppert SM, Weaver DR, Ebisawa T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron 1994;13:1177-1185.
24. 1b melatonin receptor. Proc Natl Acad Sci 1995;92:8734-8738.
25. Jockers R, Maurice P, Boutin JA, Delagrange P. Melatonin receptors, heterodimerization, signal transduction and binding sites: What's new Br J Pharmacol 2008;154:1182-1195.
26. Reppert SM, Weaver DR, Cassone VM, Godson C, Kolakowski LF Jr. Melatonin receptors are for the birds: Molecular analysis of two receptor subtypes differentially expressed in chick brain. Neuron 1995;15:1003-1015.
27. 3 as the quinone reductase 2. J Biol Chem 2000;275:31311-31317.
28. Becker-André M, Wiesenberg I, Schaeren-Wiemers N, André E, Missbach M, Saurat JH, Carlberg C. Pineal gland hormone melatonin binds and activates an orphan of the nuclear receptor superfamily. J Biol Chem 1994;269:28531-28534.
29. Hazlerigg DG, Barrett P, Hastings MH, Morgan PJ. Are nuclear receptors involved in pituitary responsiveness to melatonin Mol Cell Endocrinol 1996;123:53-59.
30. Becker-André M, Wiesenberg I, Schaeren-Wiemers N, André E, Missbach M, Saurat JH, Carlberg C. Additions and Corrections to ref. [28]. J Biol Chem 1997;272:16707.
31. Reppert SM, Weaver DR, Ebisawa T, Mahale CD, Kolakowski LF. Cloning of a melatonin-related receptor from human pituitary. FEBS Lett 1996;386:219-224.
32. Ekmekcioglu C. Melatonin receptors in humans: Biological role and clinical relevance. Biomed Pharmacother 2006;60:97-108.
33. 1 melatonin receptor. Proc Natl Acad Sci USA 2009;106:15043-15048.
34. Steinhilber D, Carlberg C. Melatonin receptor ligands. Exp Opin Ther Patents 1999;9:281-290.
35. Mor M, Plazzi PV, Spadoni G, Tarzia G. Melatonin. Curr Med Chem 1999;6:501-518.
36. Witt-Enderby PA, Li PK. Melatonin receptors and ligands. Vitam Horm 2000;58:321-354.
37. Zlotos DP. Recent advances in melatonin receptor ligands. Arch Pharm Chem Life Sci 2005;338:229-247.
38. Rivara S, Mor M, Bedini A, Spadoni G, Tarzia G. Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders. Curr Top Med Chem 2008;8:954-968.
39. Duranti E, Stankov B, Spadoni G, et al. 2-Bromomelatonin: Synthesis and characterization of a potent melatonin agonist. Life Sci 1992;51:479-485.
40. Spadoni G, Stankov B, Duranti A, Biella G, Lucini V, Salvatori A, Fraschini F. 2-Substituted 5-methoxy-N-acyltryptamines: Synthesis, binding affinity for the melatonin receptor, and evaluation of the biological activity. J Med Chem 1993;36:4069-4074.
41. Zemlan FP, Mulchahey JJ, Scharf MB, Mayleben DW, Rosenberg R, Lankford A. The efficacy and safety of the melatonin agonist beta-methyl-6-chloromelatonin in primary insomnia: A randomized, placebo-controlled, crossover clinical trial. J Clin Psychiatry 2005;66:384-390.
42. Mulchahey JJ, Goldwater DR, Zemlan FP. A single blind, placebo controlled, across groups dose escalation study of the safety, tolerability, pharmacokinetics and pharmacodynamics of the melatonin analog β-methyl-6-chloromelatonin. Life Sci 2004;75:1843-1856.
43. Yous S, Andrieux J, Howell HE, et al. Novel naphthalenic ligands with high affinity for the melatonin receptors. J Med Chem 1992;35:1484-1486.
44. Depreux P, Lesieur D, Mansour HA, et al. Synthesis and structure-activity relationships of novel naphthalenic and bioisosteric related amidic derivatives as melatonin receptor ligands. J Med Chem 1994;37:3231-3239.
45. Uchikawa O, Fukatsu K, Tokunoh R, et al. Synthesis of a novel series of tricyclic indan derivatives as melatonin receptor agonists. J Med Chem 2002;45:4222-4239.
46. Ohkawa S, Uchikawa O, Fukatsu K, Miyamoto M. PCT Int. Appl 1997; WO9705098 (A1).
47. Li P-K, Chu G-H, Gillen ML, Witt-Enderby PA. Synthesis and receptor binding studies of quinolinic derivatives as melatonin receptor ligands. Bioorg Med Chem Lett 1997;7:2177-2180.
48. Elsner J, Boeckler F, Davidson K, Sugden D, Gmeiner P. Bicyclic melatonin receptor agonists containing a ring-junction nitrogen: Synthesis, biological evaluation, and molecular modeling of the putative bioactive conformation. Bioorg Med Chem 2006;14:1949-1958.
49. Beresford IJ, Browning C, Starkey SJ, et al. GR196429: A nonindolic agonist at high-affinity melatonin receptors. J Pharmacol Exp Ther 1998;285:1239-1245.
50. Tarzia G, Diamantini G, Di Giacomo B, et al. 1-(2-Alkanamidoethyl)-6-methoxyindole derivatives: A new class of potent indole melatonin analogues. J Med Chem 1997;40:2003-2010.
51. Fourmaintraux E, Depreux P, Lesieur D, Guardiola-Lemaître B, Bennejean C, Delagrange P, Howell H. Tetrahydronaphthalenic derivatives as new agonist and antagonist ligands for melatonin receptors. Bioorg Med Chem 1998;6:9-13.
52. Copinga S, Tepper PG, Grol CJ, Horn AS, Dubocovich ML. 2-Amido-8-methoxytetralins: A series of nonindolic melatonin-like agents. J Med Chem 1993;36:2891-2898.
53. Sugden D. N-acyl-3-amino-5-methoxychromans: A new series of non-indolic melatonin analogues. Eur J Pharmacol 1994;254:271-275.
54. Garratt PJ, Travard S, Vonhoff S, Tsotinis A, Sugden D. Mapping the melatonin receptor. 4. Comparison of the binding affinities of a series of substituted phenylalkyl amides. J Med Chem 1996;39:1797-1805.
55. Rivara S, Lodola A, Mor M, et al. N-(Substituted-anilinoethyl)amides: Design, synthesis, and pharmacological characterization of a new class of melatonin receptor ligands. J Med Chem 2007;50:6618-6626.
56. Spadoni G, Balsamini C, Diamantini G, et al. Conformationally restrained melatonin analogs: Synthesis, binding affinity for the melatonin receptor, evaluation of the biological activity, and molecular modeling study. J Med Chem 1997;40:1990-2002.
57. Rivara S, Diamantini G, Di Giacomo B, et al. Reassessing the melatonin pharmacophore: Enantiomeric resolution, pharmacological activity, structure analysis, and molecular modeling of a constrained chiral melatonin analogue. Bioorg Med Chem 2006;14:3383-3391.
58. Davies DJ, Garratt PJ, Tocher DA, Vonhoff S, Davies J, Teh MT, Sugden D. Mapping the melatonin receptor. 5. Melatonin agonists and antagonists derived from tetrahydrocyclopent[b]indoles, tetrahydrocarbazoles and hexahydrocyclohept[b]indoles. J Med Chem 1998;41:451-467.
59. Sun L-Q, Chen J, Mattson RJ. Heterocyclic aminopyrrolidine derivatives as melatoninergic agents. Bioorg Med Chem Lett 2003;13:4381-4384.
60. Leclerc V, Depreux P, Lesieur D, et al. Synthesis and biological activity of conformationally restricted tricyclic analogs of the hormone melatonin. Bioorg Med Chem Lett 1996;6:1071-1076.
61. Zhdanova IV. Melatonin as a hypnotic: Pro. Sleep Med Rev 2005;9:51-65.
62. van den Heuvel CJ, Ferguson SA, Macchi MM, Dawson D. Melatonin as a hypnotic: Con. Sleep Med Rev 2005;9:71-80.
63. Wade AG, Ford I, Crawford G, McMahon AD, Nir T, Laudon M, Zisapel N. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: Quality of sleep and next-day alertness outcomes. Curr Med Res Opin 2007;23:2597-2605.
64. Lemoine P, Nir T, Laudon M, Zisapel N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res 2007;16:372-380.
65. [Assessed 27 September 2010[
66. Paul MA, Gray G, Sardana TM, Pigeau RA. Melatonin and zopiclone as facilitators of early circadian sleep in operational air transport crews. Aviat Space Environ Med 2004;75:439-443.
67. Shamir E, Laudon M, Barak Y, Anis Y, Rotenberg V, Elizur A, Zisapel N. Melatonin improves sleep quality of patients with chronic schizophrenia. J Clin Psychiatry 2000;61:373-377.
68. Dolberg OT, Hirschmann S, Grunhaus L. Melatonin for the treatment of sleep disturbances in major depressive disorder. Am J Psychiatry 1998;155:1119-11121.
69. The Committee for Medicinal Products for Human Use was concerned that the company had not demonstrated the effectiveness of Ramelteon, which was measured considering only one aspect of insomnia, the time to fall asleep. In addition, in only one of the three studies in a natural setting there was a difference in time to fall asleep between patients taking Ramelteon and those taking placebo, and this difference was considered too small to be relevant. When other aspects of sleep were considered, Ramelteon did not have any effect. The Committee was also concerned that the company had not demonstrated the long-term effectiveness of Ramelteon. Available from: [Assessed 27 September 2010.
70. [Assessed 27 September 2010]
71. McGechan A, Wellington K. Ramelteon. CNS Drugs 2005;19:1057-1065.
72. 2 melatonin receptor agonist indicated for the treatment of insomnia. J Clin Pharmacol 2006;46:140-148.
73. 2 receptor agonist. Neuropharmacology 2005;48:301-310.
74. Yukuhiro N, Kimura H, Nishikawa H, Ohkawa S, Yoshikubo S, Miyamoto M. Effects of ramelteon (TAK-375) on nocturnal sleep in freely moving monkeys. Brain Res 2004;1027:59-66.
75. Miyamoto M, Nishikawa H, Doken Y, Hirai K, Uchikawa O, Ohkawa S. The sleep-promoting action of ramelteon (TAK-375) in freely moving cats. Sleep 2004;27:1319-1325.
76. France CP, Weltman RH, Koek W, Cruz CM, McMahon LR. Acute and chronic effects of ramelteon in rhesus monkeys (Macaca mulatta): Dependence liability studies. Behav Neurosci 2006;120:535-541.
77. Hirai K, Kita M, Ohta H, Nishikawa H, Fujiwara Y, Ohkawa S, Miyamoto M. Ramelteon (TAK-375) accelerates reentrainment of circadian rhythm after a phase advance of the light-dark cycle in rats. J Biol Rhythms 2005;20:27-37.
78. 2 receptor agonist: A novel therapeutic drug for sleep disorders. CNS Neurosci Ther 2009;15:32-51.
79. Erman M, Seiden D, Zammit G, Sainati S, Zhang J. An efficacy, safety, and dose-response study of ramelteon in patients with chronic primary insomnia. Sleep Med 2006;7:17-24.
80. Zammit G, Erman M, Weigand S, Sainati S, Zhang J, Roth T. Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med 2007;3:495-504.
81. Roth T, Seiden D, Wang-Weigand S, Zhang J. A 2-night, 3-period, crossover study of ramelteon's efficacy and safety in older adults with chronic insomnia. Curr Med Res Opin 2007;23:1005-1014.
82. 2-receptor agonist, reduces latency to persistent sleep in a model of transient insomnia related to a novel sleep environment. Sleep 2005;28:303-307.
83. Griffiths RR, Suess P, Johnson M. Ramelteon and triazolam in humans: Behavioral effects and abuse potential. In: 19th Annual Meeting Associated Professional Sleep Societies, LLC. Denver, CO, 18-23 June 2005. Sleep 2005;28(Suppl):A44 [Abstract 0132.
84. US National Institute of Health. Available from: [Assessed 27 September 2010]
85. Papp M, Gruca P, Boyer PA, Mocaër E. Effect of agomelatine in the chronic mild stress model of depression in the rat. Neuropsychopharmacology 2003;28:694-703.
86. Bourin M, Mocaer E, Porsolt R. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: Involvement of melatonin and serotonin receptors. J Psychiatry Neurosci 2004;29:126-133.
87. 2C antagonist, in the treatment of major depressive disorder: A placebo-controlled dose range study. Int Clin Psychopharmacol 2002;17:239-247.
88. Kennedy S, Emsley R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur Neuropsychopharmacol 2006;16:93-100.
89. Montgomery SA, Kasper S. Severe depression and antidepressants. Focus on pooled analysis of placebo-controlled studies on agomelatine. Int Clin Psychopharmacol 2007;22:283-291.
90. 2C antagonistic properties, in major depressive disorder. Int J Neuropsychopharmacol 2007;10:661-673.
91. Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J Clin Psychopharmacol 2008;28:329-333.
92. Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: A randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol 2004;19:271-280.
93. Lemoine P, Guilleminault C, Alvarez E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant agomelatine: Randomized double-blind comparison with venlafaxine. J Clin Psychiatry 2007;68:1723-1732.
94. Pandi-Perumal SR, Moscovitch A, Srinivasan V, Spence DW, Cardinali DP, Brown GM. Bidirectional communication between sleep and circadian rhythms and its implications for depression: Lessons from agomelatine. Prog Neurobiol 2009;88:264-271.
95. Lichtenberg P, Belmaker RH. Subtyping major depressive disorder. Psycother Psychosom 2010;79:131-135.
96. Calabrese JR, Guelfi JD, Perdrizet-Chevallier C. Agomelatine adjunctive therapy for acute bipolar depression: Preliminary open data. Bipolar Disord 2007;9:628-635.
97. Pjrek E, Winkler D, Konstantinidis A, Willeit M, Praschak-Rieder N, Kasper S. Agomelatine in the treatment of seasonal affective disorder. Psychopharmacology 2007;190:575-579.
98. Rajaratnam SM, Polymeropoulos MH, Fisher DM, Roth T, Scott C, Birznieks G, Klerman EB. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: Two randomised controlled multicentre trials. Lancet 2009;373:482-491.
99. [Assessed 27 September 2010]
100. Laudon M, Peleg-Shulman T. Pyrone-indole derivatives and process for their preparation. US7, 635, 710 B2, 2009.
101. Yalkinoglu Ö, Zisapel N, Nir T, et al. Phase-I study of the safety, tolerability, pharmacokinetics and sleep promoting activity of Neu-p11, a novel putative insomnia drug in healthy humans. In: 24th Annual Meeting Associated Professional Sleep Societies, LLC. San Antonio, TX, 5-9 June 2010. Sleep 2010;33(Suppl.):A220 [Abstract 0656.
102. Tian S, Laudon M, Han L, Gao J, Huang F, Yang Y, Deng H. Antidepressant- and anxiolytic effects of the novel melatonin agonist Neu-P11 in rodent models. Acta Pharmacol Sinica 2010;31:775-783.
103. Faust R, Garratt PJ, Jones R, et al. Mapping the melatonin receptor 6. Melatonin agonists and antagonists derived from 6H-isoindolo[2, 1-a]indoles, 5, 6-dihydroindolo[2, 1-a]isoquinolines, and 6, 7-dihydro-5H-benzo-[c]azepino[2, 1-a]indoles J Med Chem 2000;43:1050-1061.
104. 2 melatonin receptor agonist in the rat. Neurosci Lett 2009;457:93-96.
105. Sanchez RO, Cohen G, Spadoni G, et al. Selective increase of Slow Wave Sleep (SWS) by a novel melatonin partial agonist. In: 37th Annual Meeting Neuroscience. San Diego, CA, 37 November 2007 [Abstract poster 735.22/UU9.
106. 2 selective agents. Bioorg Med Chem Lett 2003;13:1199-1202.
107. 2 receptor agonists. Bioorg Med Chem Lett 2004;14:1023-1026.
108. 2-selective melatonin ligands. Bioorg Med Chem Lett 2010;20:2582-2585.
109. 2 melatoninergic ligands. Bioorg Med Chem 2003;11:753-759.
110. 2 melatoninergic ligands. Bioorg Med Chem 2008;16:8339-8348.
111. 1 melatoninergic ligands. J Med Chem 2003;46:1127-1129.
112. 2 receptors. Eur J Med Chem 2004;39:515-526.
113. Di Giacomo B, Bedini A, Spadoni G, Tarzia G, Fraschini F, Pannacci M, Lucini V. Synthesis and biological activity of new melatonin dimeric derivatives. Bioorg Med Chem 2007;15:4643-4650.
114. 2 receptors. Naunyn-Schmiedeberg's Arch Pharmacol 2003;367:553-561.
115. 1 melatoninergic ligands. Bioorg Med Chem 2010;18:3426-3436.
116. Sun LQ, Chen J, Takaki K, et al. Design and synthesis of benzoxazole derivatives as novel melatoninergic ligands. Bioorg Med Chem Lett 2004;14:1197-1200.
117. Sun LQ, Chen J, Bruce M, et al. Synthesis and structure-activity relationship of novel benzoxazole derivatives as melatonin receptor agonists. Bioorg Med Chem Lett 2004;14:3799-3802.
118. Sun LQ, Takaki K, Chen J, et al. N-[2-[2-(4-Phenylbutyl)benzofuran-4-yl]cyclopropylmethyl] acetamide: An orally bioavailable melatonin receptor agonist. Bioorg Med Chem Lett 2004;14:5157-5160.
119. Sun LQ, Takaki K, Chen J, et al. (R)-2-(4-Phenylbutyl)dihydrobenzofuran derivatives as melatoninergic agents. Bioorg Med Chem Lett 2005;15:1345-1349.
120. 2-antagonist properties. J Pineal Res 2000;29:234-240.
121. 2-antagonist melatonin receptor ligands. Chem Med Chem 2006;1:1099-1105.